NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) is an aggressive form of breast cancer and is historically associated with poor outcomes compared with HER2-negative MBC. Since 1998, four drugs have been globally approved for the targeted treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Korner, Eli J., Morris, Anne, Allen, Isabel Elaine, Hurvitz, Sara, Beattie, Mary S., Kalesan, Bindu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591587/
https://www.ncbi.nlm.nih.gov/pubmed/26428301
http://dx.doi.org/10.1186/s13643-015-0118-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591587/
https://www.ncbi.nlm.nih.gov/pubmed/26428301
http://dx.doi.org/10.1186/s13643-015-0118-z

Ejemplares similares